Find clinical trials for Prostate Cancer in Toronto, ON
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Prostate Cancer trials near Toronto, ON, CAN:
177Lu PSMA 617 is a new type of therapy which is designed to deliver high doses of radiation directly to prostate cancer sites in t ...
Phase 2
Toronto, Ontario, Canada and 9 other locations
androgen deprivation therapy (ADT) with a luteinising hormone releasing hormone analogue (LHRHA) in men having radiation therapy for localised prostate...
Phase 3
Toronto, Ontario, Canada and 92 other locations
Phase 1b study to assess the combination of ARV-110 and abiraterone in patients with metastatic prostate cancer with rising PSA val...
Phase 1
Toronto, Ontario, Canada and 17 other locations
Effects of Saruparib (AZD5305) Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomy in Men with Newly Diagnosed Prostate...
Phase 1
Toronto, Ontario, Canada and 16 other locations
and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemo ...
Phase 3
Toronto, Ontario, Canada and 131 other locations
The purpose of this study is to find out what effects a new drug, palbociclib, has on prostate cancer and will look at the side eff...
Phase 2
Toronto, Ontario, Canada and 6 other locations
approach.Participants with high-risk prostate cancer planned for curative-intent standard-of-care radiotherapy or surgery, or with...
Phase 3
Toronto, Ontario, Canada and 18 other locations
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer (GUNS)
The objective of this study is to see if providing an appropriate therapy based on the genomic testing of prostate tumour tissue will result...
Phase 2
Toronto, Ontario, Canada and 4 other locations
patients with progressive metastatic castration-resistant prostate cancer (mCRPC).The following assessment of prostate cancer...
Phase 3
Oakville, Ontario, Canada and 57 other locations
hypo-fractionation (1.8-2.15Gy/fraction), both associated to an HDR prostate +/- adjacent seminal vesicles brachytherapy boost (HDR-BT)+ ADT...
Mississauga, Ontario, Canada and 10 other locations
Clinical trials
Research sites
Resources
Legal